TY - JOUR
T1 - Hstopathological features of L-asparaginase-induced liver disease
AU - Sahoo, Sunati
AU - Hart, John
PY - 2003/8/1
Y1 - 2003/8/1
N2 - We studied the histopathological changes of liver in four patients who developed hepatomegaly and abnormal liver chemistry tests 2 to 20 days following administration of L-asparaginase as a part of a combination chemotherapy regimen for treatment of acute lymphoblastic leukemia. The severity of the liver disease due to L-asparaginase was unpredictable. One patient developed acute fulminant hepatic failure and required liver transplantation. The most consistent pathological change, observed in all four cases, was diffuse steatosis. Other changes included patchy hepatocyte necrosis, mixed inflammatory cell infiltrates in the portal tracts, and variable degrees of hepatocellular, or canalicular cholestasis, or a combination of these.
AB - We studied the histopathological changes of liver in four patients who developed hepatomegaly and abnormal liver chemistry tests 2 to 20 days following administration of L-asparaginase as a part of a combination chemotherapy regimen for treatment of acute lymphoblastic leukemia. The severity of the liver disease due to L-asparaginase was unpredictable. One patient developed acute fulminant hepatic failure and required liver transplantation. The most consistent pathological change, observed in all four cases, was diffuse steatosis. Other changes included patchy hepatocyte necrosis, mixed inflammatory cell infiltrates in the portal tracts, and variable degrees of hepatocellular, or canalicular cholestasis, or a combination of these.
KW - Drug-induced liver disease
KW - L-asparaginase toxity
KW - Steatosis
UR - http://www.scopus.com/inward/record.url?scp=0041317567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041317567&partnerID=8YFLogxK
U2 - 10.1055/s-2003-42647
DO - 10.1055/s-2003-42647
M3 - Review article
C2 - 14523682
AN - SCOPUS:0041317567
SN - 0272-8087
VL - 23
SP - 295
EP - 299
JO - Seminars in liver disease
JF - Seminars in liver disease
IS - 3
ER -